



## Clinical trial results:

### AdvanTIG-205: A Phase 2, Randomized Study of Ociperlimab (BGB-A1217) and Tislelizumab With Chemotherapy in Patients With Previously Untreated Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer (NSCLC)

#### Summary

EudraCT number	2021-001075-17
Trial protocol	ES AT PL
Global end of trial date	04 September 2024

#### Results information

Result version number	v1 (current)
This version publication date	13 September 2025
First version publication date	13 September 2025

#### Trial information

##### Trial identification

Sponsor protocol code	AdvanTIG-205
-----------------------	--------------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT05014815
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	BeiGene
Sponsor organisation address	1840 Gateway Drive, San Mateo, CA , United States, 94404
Public contact	BeiGene Clinical Support, BeiGene USA, Inc., 1 877-828-5568, ClinicalTrials@beigene.com
Scientific contact	BeiGene Clinical Support, BeiGene USA, Inc., 1 877-828-5568, ClinicalTrials@beigene.com

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	04 September 2024
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	04 September 2024
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

This study aimed to evaluate the safety and effectiveness of ociperlimab combined with tislelizumab and chemotherapy, compared to tislelizumab and chemotherapy alone, in participants with non-small cell lung cancer (NSCLC) that was locally advanced, could not be removed by surgery, or had spread to other parts of the body.

Protection of trial subjects:

This study was conducted in accordance with sponsor procedures, which comply with the principles of Good Clinical Practice (GCP), International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Guidelines, the Declaration of Helsinki, and applicable local regulatory requirements.

The protocol, any amendments, and informed consent forms were reviewed and approved by the Independent Ethics Committee/Institutional Review Board in conformance with GCP and applicable regulatory requirements.

Before a patient was enrolled in the study, he or she was provided with a written informed consent form that complied with GCP. The investigator (or designee) explained to each patient the nature of the study, its purpose, procedures, expected duration, and the benefits and risks involved with study participation. Patients were given the opportunity to ask questions and were informed of their right to withdraw from the study at any time without prejudice. After this explanation and before enrolling in the study, patients or their legal representatives signed 2 copies of the informed consent form (one copy for the patient and the other for filing with the patient's study records). Informed consent was obtained before any screening or study-specific procedures were performed.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	16 November 2021
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	China: 164
Country: Number of subjects enrolled	Australia: 16
Country: Number of subjects enrolled	France: 8
Country: Number of subjects enrolled	Spain: 13
Country: Number of subjects enrolled	Austria: 1
Country: Number of subjects enrolled	Greece: 1
Country: Number of subjects enrolled	United States: 27
Country: Number of subjects enrolled	Korea, Republic of: 42

Worldwide total number of subjects	272
EEA total number of subjects	23

Notes:

---

**Subjects enrolled per age group**

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	133
From 65 to 84 years	138
85 years and over	1

## Subject disposition

### Recruitment

Recruitment details:

This study was conducted at 75 study centers in 8 countries (China, South Korea, United States of America, Australia, France, Spain, Austria, Greece).

### Pre-assignment

Screening details:

Eligible participants were randomized in a 1:1 ratio to receive either ociperlimab or placebo treatment, plus tislelizumab and chemotherapy. Randomization was stratified by histology (squamous versus non-squamous), and programmed cell death protein ligand-1 (PD-L1) expression.

### Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Arm A (O+T+C)

Arm description:

During the induction phase, participants received ociperlimab (O) 900 mg IV, tislelizumab (T) 200 mg IV, and histology-based chemotherapy (C) every 21 days for 4-6 cycles. For squamous NSCLC, chemotherapy included carboplatin AUC 5 or 6 (on Day 1) + paclitaxel 175 or 200 mg/m<sup>2</sup> (Day 1) or nab-paclitaxel 100 mg/m<sup>2</sup> (Days 1, 8, 15) every 3 weeks. For non-squamous NSCLC, chemotherapy included cisplatin 75 mg/m<sup>2</sup> or carboplatin AUC 5 (Day 1) + pemetrexed (P) 500 mg/m<sup>2</sup> IV (Day 1), every 3 weeks.

In the maintenance phase, non-squamous NSCLC participants received O 900 mg IV, T 200 mg IV, and pemetrexed 500 mg/m<sup>2</sup> IV every 3 weeks. Squamous NSCLC participants received O 900 mg IV and T 200 mg IV every 3 weeks until toxicity, consent withdrawal, or investigator-determined lack of benefit.

Arm type	Experimental
Investigational medicinal product name	Ociperlimab
Investigational medicinal product code	BGB-A1217
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

900 mg intravenously (IV) once every 3 weeks (Q3W)

Investigational medicinal product name	Tislelizumab
Investigational medicinal product code	BGB-A1217
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

200 mg IV Q3W

Investigational medicinal product name	Paclitaxel
Investigational medicinal product code	
Other name	

Pharmaceutical forms	Solution for infusion
Routes of administration	Infusion
Dosage and administration details:	
75 or 200 mg per square meter (mg/m <sup>2</sup> ) of body surface area, administered on Day 1 of each 21-day cycle	
Investigational medicinal product name	Nab paclitaxel
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Infusion
Dosage and administration details:	
100 mg/m <sup>2</sup> , administered intravenously on Days 1, 8, and 15 of each 21-day cycle	
Investigational medicinal product name	Cisplatin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Infusion
Dosage and administration details:	
75 mg/m <sup>2</sup> , administered intravenously on Day 1 of each 21-day cycle	
Investigational medicinal product name	Pemetrexed
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Infusion
Dosage and administration details:	
500 mg/m <sup>2</sup> administered intravenously on Day 1 of each 21-day cycle	
<b>Arm title</b>	Arm B (P+T+C)
Arm description:	
During the induction phase, participants received placebo (P) 900 mg IV, tislelizumab (T) 200 mg IV, and histology-based chemotherapy (C) every 21 days for 4-6 cycles. For squamous NSCLC, chemotherapy included carboplatin AUC 5 or 6 (Day 1) + paclitaxel 175 or 200 mg/m <sup>2</sup> (Day 1) or nab-paclitaxel 100 mg/m <sup>2</sup> (Days 1, 8, 15) every 3 weeks. For non-squamous NSCLC, chemotherapy included cisplatin 75 mg/m <sup>2</sup> or carboplatin AUC 5 (Day 1) + pemetrexed (P) 500 mg/m <sup>2</sup> IV (Day 1), every 3 weeks.	
In the maintenance phase, non-squamous NSCLC participants received placebo 900 mg IV, T 200 mg IV, and pemetrexed 500 mg/m <sup>2</sup> IV every 3 weeks. Squamous NSCLC participants received placebo IV and T 200 mg IV every 3 weeks until toxicity, consent withdrawal, or investigator-determined lack of benefit.	
Arm type	Placebo
Investigational medicinal product name	Tislelizumab
Investigational medicinal product code	
Other name	BGB-A317
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use
Dosage and administration details:	
200 mg IV Q3W	
Investigational medicinal product name	Paclitaxel
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Infusion
Dosage and administration details:	
75 or 200 mg per square meter (mg/m <sup>2</sup> ) of body surface area, administered on Day 1 of each 21-day cycle	

Investigational medicinal product name	Nab paclitaxel
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Infusion
Dosage and administration details:	
100 mg/m <sup>2</sup> , administered intravenously on Days 1, 8, and 15 of each 21-day cycle	
Investigational medicinal product name	Cisplatin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Infusion
Dosage and administration details:	
75 mg/m <sup>2</sup> , administered intravenously on Day 1 of each 21-day cycle	
Investigational medicinal product name	Pemetrexed
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Infusion
Dosage and administration details:	
500 mg/m <sup>2</sup> administered intravenously on Day 1 of each 21-day cycle	

<b>Number of subjects in period 1</b>	Arm A (O+T+C)	Arm B (P+T+C)
Started	136	136
Treated	135	136
Completed	57	50
Not completed	79	86
Consent withdrawn by subject	10	10
Physician decision	2	4
Death	63	70
Lost to follow-up	4	2

## Baseline characteristics

### Reporting groups

Reporting group title	Arm A (O+T+C)
-----------------------	---------------

Reporting group description:

During the induction phase, participants received ociperlimab (O) 900 mg IV, tislelizumab (T) 200 mg IV, and histology-based chemotherapy (C) every 21 days for 4-6 cycles. For squamous NSCLC, chemotherapy included carboplatin AUC 5 or 6 (on Day 1) + paclitaxel 175 or 200 mg/m<sup>2</sup> (Day 1) or nab-paclitaxel 100 mg/m<sup>2</sup> (Days 1, 8, 15) every 3 weeks. For non-squamous NSCLC, chemotherapy included cisplatin 75 mg/m<sup>2</sup> or carboplatin AUC 5 (Day 1) + pemetrexed (P) 500 mg/m<sup>2</sup> IV (Day 1), every 3 weeks.

In the maintenance phase, non-squamous NSCLC participants received O 900 mg IV, T 200 mg IV, and pemetrexed 500 mg/m<sup>2</sup> IV every 3 weeks. Squamous NSCLC participants received O 900 mg IV and T 200 mg IV every 3 weeks until toxicity, consent withdrawal, or investigator-determined lack of benefit.

Reporting group title	Arm B (P+T+C)
-----------------------	---------------

Reporting group description:

During the induction phase, participants received placebo (P) 900 mg IV, tislelizumab (T) 200 mg IV, and histology-based chemotherapy (C) every 21 days for 4-6 cycles. For squamous NSCLC, chemotherapy included carboplatin AUC 5 or 6 (Day 1) + paclitaxel 175 or 200 mg/m<sup>2</sup> (Day 1) or nab-paclitaxel 100 mg/m<sup>2</sup> (Days 1, 8, 15) every 3 weeks. For non-squamous NSCLC, chemotherapy included cisplatin 75 mg/m<sup>2</sup> or carboplatin AUC 5 (Day 1) + pemetrexed (P) 500 mg/m<sup>2</sup> IV (Day 1), every 3 weeks.

In the maintenance phase, non-squamous NSCLC participants received placebo 900 mg IV, T 200 mg IV, and pemetrexed 500 mg/m<sup>2</sup> IV every 3 weeks. Squamous NSCLC participants received placebo IV and T 200 mg IV every 3 weeks until toxicity, consent withdrawal, or investigator-determined lack of benefit.

Reporting group values	Arm A (O+T+C)	Arm B (P+T+C)	Total
Number of subjects	136	136	272
Age categorical			
Units: Subjects			

Age continuous			
Units: years			
geometric mean	64.02	63.77	
standard deviation	± 8.006	± 9.366	-
Gender categorical			
Units: Subjects			
Female	22	32	54
Male	114	104	218
Ethnicity			
Units: Subjects			
Hispanic or Latino	1	4	5
Not Hispanic or Latino	123	123	246
Unknown	4	2	6
Not Reported	8	7	15
Histology			
Histology stratification refers to the classification of participants based on tumor cell morphology. Squamous histology is defined by malignant transformation of flat epithelial cells typically lining the airways, while nonsquamous histology includes adenocarcinoma, large cell carcinoma, and other subtypes arising from glandular or poorly differentiated epithelial cells.			
Units: Subjects			

Squamous	55	56	111
Non-Squamous	81	80	161
PD-L1 Expression			
PD-L1 is a protein that can help cancer cells avoid being killed by the immune system. PD-L1 score was based on the % of tumor area with PD-L1-stained tumor or immune cells, using the TAP (Tumor Area Positive) Score method, previously called vCPS. Scores were obtained via Interactive Response Technology.			
Units: Subjects			
< 1% of tumor cells	57	58	115
1-49% of Tumor Cells	42	42	84
> 50% of Tumor Cells	37	36	73



## End points

### End points reporting groups

Reporting group title	Arm A (O+T+C)
Reporting group description:	
During the induction phase, participants received ociperlimab (O) 900 mg IV, tislelizumab (T) 200 mg IV, and histology-based chemotherapy (C) every 21 days for 4-6 cycles. For squamous NSCLC, chemotherapy included carboplatin AUC 5 or 6 (on Day 1) + paclitaxel 175 or 200 mg/m <sup>2</sup> (Day 1) or nab-paclitaxel 100 mg/m <sup>2</sup> (Days 1, 8, 15) every 3 weeks. For non-squamous NSCLC, chemotherapy included cisplatin 75 mg/m <sup>2</sup> or carboplatin AUC 5 (Day 1) + pemetrexed (P) 500 mg/m <sup>2</sup> IV (Day 1), every 3 weeks.	
In the maintenance phase, non-squamous NSCLC participants received O 900 mg IV, T 200 mg IV, and pemetrexed 500 mg/m <sup>2</sup> IV every 3 weeks. Squamous NSCLC participants received O 900 mg IV and T 200 mg IV every 3 weeks until toxicity, consent withdrawal, or investigator-determined lack of benefit.	
Reporting group title	Arm B (P+T+C)
Reporting group description:	
During the induction phase, participants received placebo (P) 900 mg IV, tislelizumab (T) 200 mg IV, and histology-based chemotherapy (C) every 21 days for 4-6 cycles. For squamous NSCLC, chemotherapy included carboplatin AUC 5 or 6 (Day 1) + paclitaxel 175 or 200 mg/m <sup>2</sup> (Day 1) or nab-paclitaxel 100 mg/m <sup>2</sup> (Days 1, 8, 15) every 3 weeks. For non-squamous NSCLC, chemotherapy included cisplatin 75 mg/m <sup>2</sup> or carboplatin AUC 5 (Day 1) + pemetrexed (P) 500 mg/m <sup>2</sup> IV (Day 1), every 3 weeks.	
In the maintenance phase, non-squamous NSCLC participants received placebo 900 mg IV, T 200 mg IV, and pemetrexed 500 mg/m <sup>2</sup> IV every 3 weeks. Squamous NSCLC participants received placebo IV and T 200 mg IV every 3 weeks until toxicity, consent withdrawal, or investigator-determined lack of benefit.	

### Primary: Progression-free Survival (PFS)

End point title	Progression-free Survival (PFS)
End point description:	
PFS was defined as the time from randomization to the first objectively documented disease progression as assessed by the investigator per RECIST v1.1 or death from any cause, whichever occurred first. Median PFS was estimated using the Kaplan-Meier method.	
Intent-To-Treat Analysis Set	
End point type	Primary
End point timeframe:	
From randomization up to the final efficacy analysis data cut-off date of 04 September 2024; Up to 33 months	

End point values	Arm A (O+T+C)	Arm B (P+T+C)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	136	136		
Units: Months				
median (confidence interval 95%)	8.2 (6.2 to 10.6)	8.1 (6.0 to 10.2)		

## Statistical analyses

<b>Statistical analysis title</b>	Progression-free Survival (PFS)
Statistical analysis description: The HR and its 95% confidence interval (CI) was estimated using a Cox regression model stratified by PD-L1 expression (<1% of tumor cells (TC) vs 1-49% TC vs >= 50% TC) and histology (squamous vs non-squamous).	
Comparison groups	Arm A (O+T+C) v Arm B (P+T+C)
Number of subjects included in analysis	272
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.4698 <sup>[1]</sup>
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.99
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.74
upper limit	1.33

Notes:

[1] - The p-value was calculated using a log-rank test stratified by PD-L1 expression (<1 % TC vs 1 - 49 % TC vs >= 50 % TC) and histology (squamous vs non-squamous).

## Secondary: Objective Response Rate (ORR)

End point title	Objective Response Rate (ORR)
End point description: Objective response rate is defined as the percentage of participants who had a confirmed complete response (CR) or partial response (PR) as assessed by the investigator per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 Tumor assessments. CR is defined as the disappearance of all target and non-target lesions and no new lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.	
Intent-To-Treat Analysis Set	
End point type	Secondary
End point timeframe: From randomization up to the final efficacy analysis data cut-off date of 04 September 2024; Up to 33 months	

End point values	Arm A (O+T+C)	Arm B (P+T+C)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	136	136		
Units: Percentage of Participants				
median (confidence interval 95%)	41.9 (33.5 to 50.7)	47.8 (39.2 to 56.5)		

## Statistical analyses

Statistical analysis title	Objective Response Rate (ORR)
Statistical analysis description:	
The Mantel-Haenszel common OR and its 95% CI were estimated using a normal approximation of the log odds ratio and the Robins-Breslow-Greenland variance, stratified by PD-L1 expression and histology.	
Comparison groups	Arm A (O+T+C) v Arm B (P+T+C)
Number of subjects included in analysis	272
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Odds ratio (OR)
Point estimate	0.77
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.47
upper limit	1.26

## Secondary: Duration of Response (DOR)

End point title	Duration of Response (DOR)
End point description:	
DOR was defined as the time from the first documented objective response to documented radiological disease progression as assessed by the investigator using RECIST v1.1, or death from any cause, whichever occurred first. Median DOR was estimated using the Kaplan-Meier method.	
Progressive disease is captured as at least a 20% increase in the sum of diameters of target lesions using the smallest sum on study as the reference (including the baseline sum if it was the smallest). In addition to the 20% relative increase, the sum also had to show an absolute increase of at least 5 mm.	
The analysis included only intent-to-treat participants with a confirmed complete or partial response per RECIST v1.1.	
End point type	Secondary
End point timeframe:	
From randomization up to the final efficacy analysis data cut-off date of 04 September 2024; Up to 33 months	

End point values	Arm A (O+T+C)	Arm B (P+T+C)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	57	65		
Units: Months				
median (confidence interval 95%)	10.4 (8.0 to 17.7)	11.2 (8.1 to 13.9)		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Overall Survival (OS)

End point title	Overall Survival (OS)
-----------------	-----------------------

End point description:

OS was defined as the time from randomization to the documented date of death for participants who died on or before the clinical cutoff date. Median OS was calculated using the Kaplan-Meier method. Data for participants who were alive at the clinical cutoff date were censored at their last known alive date, defined as either the clinical cutoff date for those still on treatment or the most recent available date confirming they were alive, whichever occurred first.

End point type	Secondary
----------------	-----------

End point timeframe:

From randomization up to the final efficacy analysis data cut-off date of 04 September 2024; Up to 33 months

End point values	Arm A (O+T+C)	Arm B (P+T+C)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	136	136		
Units: Months				
median (confidence interval 95%)	20.6 (14.4 to 99999)	19.4 (15.4 to 23.1)		

## Statistical analyses

Statistical analysis title	Overall Survival (OS)
----------------------------	-----------------------

Statistical analysis description:

The HR and its 95% confidence interval (CI) was estimated using a Cox regression model stratified by PD-L1 expression (<1% of tumor cells (TC) vs 1-49% TC vs ≥ 50% TC) and histology (squamous vs non-squamous).

Comparison groups	Arm A (O+T+C) v Arm B (P+T+C)
-------------------	-------------------------------

Number of subjects included in analysis	272
Analysis specification	Pre-specified
Analysis type	other
Parameter estimate	Hazard ratio (HR)
Point estimate	0.95
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.67
upper limit	1.34

---

### Secondary: Number of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

---

End point title	Number of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
-----------------	---

#### End point description:

The number of participants who experienced TEAEs and SAEs was reported. An adverse event refers to any unintended or unfavorable sign, symptom, or condition (including abnormal lab results) that occurs during the study, regardless of whether it is linked to the study drug. Investigators evaluated the severity of each adverse event according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.

The Safety Analysis Set included all randomized participants who received at least one dose of the study drug.

End point type	Secondary
----------------	-----------

#### End point timeframe:

From first dose of study drug to 30 days after last dose, up to the study completion date cut-off date of 04 September 2024 (up to 32.4 months)

---

End point values	Arm A (O+T+C)	Arm B (P+T+C)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	135	136		
Units: Participants				
Number of participants with any TEAEs	134	135		
Number of participants with SAEs	63	74		

### Statistical analyses

---

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

All-cause mortality is reported from randomization up to study completion date cut-off date of 04 September 2024, up to 33 months. AEs are reported from first dose of study drug to 30 days after last dose, up to study completion date (up to 32.4 months).

Adverse event reporting additional description:

All-cause mortality is reported for all randomized participants. Serious and other adverse events are based on all randomized participants who received  $\geq 1$  dose of any study treatment.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
Dictionary version	26

### Reporting groups

Reporting group title	Arm A (O+T+C)
-----------------------	---------------

Reporting group description:

Ociperlimab (900 mg IV), tislelizumab (200 mg IV), and histology-based chemotherapy

Reporting group title	Arm B (P+T+C)
-----------------------	---------------

Reporting group description:

Placebo, tislelizumab (200 mg IV), and histology-based chemotherapy

Serious adverse events	Arm A (O+T+C)	Arm B (P+T+C)	
Total subjects affected by serious adverse events			
subjects affected / exposed	74 / 136 (54.41%)	63 / 135 (46.67%)	
number of deaths (all causes)	70	63	
number of deaths resulting from adverse events	11	15	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Acute myeloid leukaemia			
subjects affected / exposed	1 / 136 (0.74%)	0 / 135 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Breast cancer			
subjects affected / exposed	1 / 136 (0.74%)	0 / 135 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malignant pleural effusion			

subjects affected / exposed	1 / 136 (0.74%)	0 / 135 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular disorders			
Venous thrombosis limb			
subjects affected / exposed	1 / 136 (0.74%)	0 / 135 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypotension			
subjects affected / exposed	1 / 136 (0.74%)	2 / 135 (1.48%)	
occurrences causally related to treatment / all	0 / 1	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Chills			
subjects affected / exposed	0 / 136 (0.00%)	1 / 135 (0.74%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Death			
subjects affected / exposed	0 / 136 (0.00%)	2 / 135 (1.48%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 2	
Face oedema			
subjects affected / exposed	0 / 136 (0.00%)	1 / 135 (0.74%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chest discomfort			
subjects affected / exposed	1 / 136 (0.74%)	0 / 135 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Asthenia			
subjects affected / exposed	1 / 136 (0.74%)	0 / 135 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Fatigue			
subjects affected / exposed	1 / 136 (0.74%)	0 / 135 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pain			
subjects affected / exposed	0 / 136 (0.00%)	1 / 135 (0.74%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oedema peripheral			
subjects affected / exposed	1 / 136 (0.74%)	1 / 135 (0.74%)	
occurrences causally related to treatment / all	1 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Non-cardiac chest pain			
subjects affected / exposed	0 / 136 (0.00%)	1 / 135 (0.74%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Multiple organ dysfunction syndrome			
subjects affected / exposed	1 / 136 (0.74%)	0 / 135 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Generalised oedema			
subjects affected / exposed	0 / 136 (0.00%)	1 / 135 (0.74%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
General physical health deterioration			
subjects affected / exposed	0 / 136 (0.00%)	1 / 135 (0.74%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Pyrexia			
subjects affected / exposed	2 / 136 (1.47%)	5 / 135 (3.70%)	
occurrences causally related to treatment / all	1 / 2	5 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			



Cough			
subjects affected / exposed	0 / 136 (0.00%)	1 / 135 (0.74%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dyspnoea			
subjects affected / exposed	1 / 136 (0.74%)	3 / 135 (2.22%)	
occurrences causally related to treatment / all	0 / 1	1 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemoptysis			
subjects affected / exposed	2 / 136 (1.47%)	3 / 135 (2.22%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 1	
Hypoxia			
subjects affected / exposed	1 / 136 (0.74%)	1 / 135 (0.74%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Interstitial lung disease			
subjects affected / exposed	1 / 136 (0.74%)	0 / 135 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pleural effusion			
subjects affected / exposed	2 / 136 (1.47%)	2 / 135 (1.48%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonitis			
subjects affected / exposed	4 / 136 (2.94%)	1 / 135 (0.74%)	
occurrences causally related to treatment / all	4 / 4	1 / 1	
deaths causally related to treatment / all	1 / 1	0 / 0	
Pneumothorax			
subjects affected / exposed	0 / 136 (0.00%)	1 / 135 (0.74%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary artery thrombosis			

subjects affected / exposed	0 / 136 (0.00%)	1 / 135 (0.74%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary embolism			
subjects affected / exposed	1 / 136 (0.74%)	4 / 135 (2.96%)	
occurrences causally related to treatment / all	0 / 1	1 / 4	
deaths causally related to treatment / all	0 / 0	0 / 1	
Respiratory failure			
subjects affected / exposed	0 / 136 (0.00%)	5 / 135 (3.70%)	
occurrences causally related to treatment / all	0 / 0	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 3	
Immune-mediated lung disease			
subjects affected / exposed	1 / 136 (0.74%)	0 / 135 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	1 / 1	0 / 0	
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	0 / 136 (0.00%)	1 / 135 (0.74%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 136 (0.00%)	1 / 135 (0.74%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood bilirubin increased			
subjects affected / exposed	0 / 136 (0.00%)	1 / 135 (0.74%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood creatinine increased			
subjects affected / exposed	1 / 136 (0.74%)	2 / 135 (1.48%)	
occurrences causally related to treatment / all	1 / 1	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neutrophil count decreased			

subjects affected / exposed	3 / 136 (2.21%)	5 / 135 (3.70%)	
occurrences causally related to treatment / all	3 / 3	7 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Platelet count decreased			
subjects affected / exposed	5 / 136 (3.68%)	3 / 135 (2.22%)	
occurrences causally related to treatment / all	5 / 5	5 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Troponin increased			
subjects affected / exposed	0 / 136 (0.00%)	1 / 135 (0.74%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Weight decreased			
subjects affected / exposed	0 / 136 (0.00%)	1 / 135 (0.74%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
White blood cell count decreased			
subjects affected / exposed	4 / 136 (2.94%)	5 / 135 (3.70%)	
occurrences causally related to treatment / all	4 / 4	6 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
Thoracic vertebral fracture			
subjects affected / exposed	0 / 136 (0.00%)	1 / 135 (0.74%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Foot fracture			
subjects affected / exposed	1 / 136 (0.74%)	0 / 135 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hip fracture			
subjects affected / exposed	1 / 136 (0.74%)	0 / 135 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			

Acute myocardial infarction			
subjects affected / exposed	0 / 136 (0.00%)	1 / 135 (0.74%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Atrial fibrillation			
subjects affected / exposed	1 / 136 (0.74%)	1 / 135 (0.74%)	
occurrences causally related to treatment / all	1 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pericardial effusion			
subjects affected / exposed	0 / 136 (0.00%)	1 / 135 (0.74%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myocardial infarction			
subjects affected / exposed	0 / 136 (0.00%)	1 / 135 (0.74%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Immune-mediated myocarditis			
subjects affected / exposed	2 / 136 (1.47%)	1 / 135 (0.74%)	
occurrences causally related to treatment / all	2 / 2	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiopulmonary failure			
subjects affected / exposed	1 / 136 (0.74%)	1 / 135 (0.74%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Cardio-respiratory arrest			
subjects affected / exposed	1 / 136 (0.74%)	0 / 135 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Tachycardia			
subjects affected / exposed	1 / 136 (0.74%)	0 / 135 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			

Brain oedema			
subjects affected / exposed	1 / 136 (0.74%)	0 / 135 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cerebral infarction			
subjects affected / exposed	1 / 136 (0.74%)	0 / 135 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhage intracranial			
subjects affected / exposed	1 / 136 (0.74%)	0 / 135 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Immune-mediated encephalitis			
subjects affected / exposed	1 / 136 (0.74%)	0 / 135 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lacunar infarction			
subjects affected / exposed	0 / 136 (0.00%)	1 / 135 (0.74%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	5 / 136 (3.68%)	4 / 135 (2.96%)	
occurrences causally related to treatment / all	5 / 5	6 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Leukopenia			
subjects affected / exposed	1 / 136 (0.74%)	3 / 135 (2.22%)	
occurrences causally related to treatment / all	1 / 1	4 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Febrile neutropenia			
subjects affected / exposed	4 / 136 (2.94%)	4 / 135 (2.96%)	
occurrences causally related to treatment / all	5 / 5	4 / 4	
deaths causally related to treatment / all	1 / 1	0 / 0	
Coagulopathy			

subjects affected / exposed	0 / 136 (0.00%)	1 / 135 (0.74%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	1 / 1	
Thrombocytopenia			
subjects affected / exposed	2 / 136 (1.47%)	1 / 135 (0.74%)	
occurrences causally related to treatment / all	2 / 2	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neutropenia			
subjects affected / exposed	2 / 136 (1.47%)	2 / 135 (1.48%)	
occurrences causally related to treatment / all	2 / 2	2 / 2	
deaths causally related to treatment / all	1 / 1	0 / 0	
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	2 / 136 (1.47%)	0 / 135 (0.00%)	
occurrences causally related to treatment / all	2 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal pain			
subjects affected / exposed	0 / 136 (0.00%)	1 / 135 (0.74%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vomiting			
subjects affected / exposed	0 / 136 (0.00%)	1 / 135 (0.74%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Upper gastrointestinal haemorrhage			
subjects affected / exposed	1 / 136 (0.74%)	0 / 135 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nausea			
subjects affected / exposed	2 / 136 (1.47%)	1 / 135 (0.74%)	
occurrences causally related to treatment / all	2 / 2	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intra-abdominal fluid collection			

subjects affected / exposed	1 / 136 (0.74%)	0 / 135 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Immune-mediated pancreatitis			
subjects affected / exposed	1 / 136 (0.74%)	0 / 135 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Immune-mediated enterocolitis			
subjects affected / exposed	3 / 136 (2.21%)	0 / 135 (0.00%)	
occurrences causally related to treatment / all	4 / 4	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal inflammation			
subjects affected / exposed	1 / 136 (0.74%)	0 / 135 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal haemorrhage			
subjects affected / exposed	1 / 136 (0.74%)	0 / 135 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric haemorrhage			
subjects affected / exposed	1 / 136 (0.74%)	0 / 135 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	1 / 1	0 / 0	
Duodenal ulcer			
subjects affected / exposed	0 / 136 (0.00%)	1 / 135 (0.74%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			
Cholecystitis			
subjects affected / exposed	0 / 136 (0.00%)	1 / 135 (0.74%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cholecystitis acute			

subjects affected / exposed	0 / 136 (0.00%)	1 / 135 (0.74%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic failure			
subjects affected / exposed	0 / 136 (0.00%)	1 / 135 (0.74%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatic function abnormal			
subjects affected / exposed	1 / 136 (0.74%)	0 / 135 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatitis			
subjects affected / exposed	1 / 136 (0.74%)	0 / 135 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Immune-mediated hepatitis			
subjects affected / exposed	1 / 136 (0.74%)	0 / 135 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute hepatic failure			
subjects affected / exposed	0 / 136 (0.00%)	1 / 135 (0.74%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	1 / 1	
Skin and subcutaneous tissue disorders			
Dermatitis allergic			
subjects affected / exposed	0 / 136 (0.00%)	1 / 135 (0.74%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Immune-mediated dermatitis			
subjects affected / exposed	1 / 136 (0.74%)	0 / 135 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pruritus			



subjects affected / exposed	0 / 136 (0.00%)	1 / 135 (0.74%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pseudocellulitis			
subjects affected / exposed	0 / 136 (0.00%)	1 / 135 (0.74%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	1 / 136 (0.74%)	1 / 135 (0.74%)	
occurrences causally related to treatment / all	1 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic kidney disease			
subjects affected / exposed	1 / 136 (0.74%)	0 / 135 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Immune-mediated nephritis			
subjects affected / exposed	1 / 136 (0.74%)	1 / 135 (0.74%)	
occurrences causally related to treatment / all	1 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	1 / 136 (0.74%)	0 / 135 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bone pain			
subjects affected / exposed	1 / 136 (0.74%)	0 / 135 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Immune-mediated myositis			
subjects affected / exposed	1 / 136 (0.74%)	0 / 135 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Myalgia			
subjects affected / exposed	1 / 136 (0.74%)	1 / 135 (0.74%)	
occurrences causally related to treatment / all	1 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myositis			
subjects affected / exposed	1 / 136 (0.74%)	0 / 135 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pain in extremity			
subjects affected / exposed	0 / 136 (0.00%)	1 / 135 (0.74%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Pneumonia staphylococcal			
subjects affected / exposed	0 / 136 (0.00%)	1 / 135 (0.74%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchitis			
subjects affected / exposed	1 / 136 (0.74%)	0 / 135 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
COVID-19			
subjects affected / exposed	1 / 136 (0.74%)	0 / 135 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
COVID-19 pneumonia			
subjects affected / exposed	4 / 136 (2.94%)	0 / 135 (0.00%)	
occurrences causally related to treatment / all	0 / 5	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cellulitis			
subjects affected / exposed	1 / 136 (0.74%)	0 / 135 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Clostridium difficile infection			

subjects affected / exposed	1 / 136 (0.74%)	0 / 135 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Focal peritonitis			
subjects affected / exposed	0 / 136 (0.00%)	1 / 135 (0.74%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haematological infection			
subjects affected / exposed	1 / 136 (0.74%)	0 / 135 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia			
subjects affected / exposed	13 / 136 (9.56%)	10 / 135 (7.41%)	
occurrences causally related to treatment / all	4 / 15	4 / 10	
deaths causally related to treatment / all	0 / 1	0 / 1	
Neutropenic sepsis			
subjects affected / exposed	1 / 136 (0.74%)	0 / 135 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung abscess			
subjects affected / exposed	0 / 136 (0.00%)	1 / 135 (0.74%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Klebsiella sepsis			
subjects affected / exposed	0 / 136 (0.00%)	1 / 135 (0.74%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Kidney infection			
subjects affected / exposed	0 / 136 (0.00%)	1 / 135 (0.74%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Influenza			

subjects affected / exposed	2 / 136 (1.47%)	0 / 135 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary tuberculosis			
subjects affected / exposed	0 / 136 (0.00%)	1 / 135 (0.74%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory tract infection			
subjects affected / exposed	0 / 136 (0.00%)	1 / 135 (0.74%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sepsis			
subjects affected / exposed	2 / 136 (1.47%)	1 / 135 (0.74%)	
occurrences causally related to treatment / all	1 / 2	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 1	
Septic shock			
subjects affected / exposed	1 / 136 (0.74%)	1 / 135 (0.74%)	
occurrences causally related to treatment / all	1 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Upper respiratory tract infection			
subjects affected / exposed	1 / 136 (0.74%)	0 / 135 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract infection			
subjects affected / exposed	1 / 136 (0.74%)	2 / 135 (1.48%)	
occurrences causally related to treatment / all	1 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	0 / 136 (0.00%)	1 / 135 (0.74%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Electrolyte imbalance			

subjects affected / exposed	0 / 136 (0.00%)	1 / 135 (0.74%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperglycaemia			
subjects affected / exposed	1 / 136 (0.74%)	0 / 135 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperkalaemia			
subjects affected / exposed	1 / 136 (0.74%)	0 / 135 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoalbuminaemia			
subjects affected / exposed	1 / 136 (0.74%)	0 / 135 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypokalaemia			
subjects affected / exposed	0 / 136 (0.00%)	1 / 135 (0.74%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyponatraemia			
subjects affected / exposed	1 / 136 (0.74%)	0 / 135 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Type 2 diabetes mellitus			
subjects affected / exposed	1 / 136 (0.74%)	0 / 135 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 3 %

<b>Non-serious adverse events</b>	Arm A (O+T+C)	Arm B (P+T+C)	
Total subjects affected by non-serious adverse events subjects affected / exposed	132 / 136 (97.06%)	132 / 135 (97.78%)	
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Cancer pain subjects affected / exposed occurrences (all)	6 / 136 (4.41%) 6	3 / 135 (2.22%) 3	
Vascular disorders Hypotension subjects affected / exposed occurrences (all)  Hypertension subjects affected / exposed occurrences (all)	3 / 136 (2.21%) 3  5 / 136 (3.68%) 5	6 / 135 (4.44%) 6  4 / 135 (2.96%) 4	
General disorders and administration site conditions Asthenia subjects affected / exposed occurrences (all)  Fatigue subjects affected / exposed occurrences (all)  Malaise subjects affected / exposed occurrences (all)  Oedema peripheral subjects affected / exposed occurrences (all)  Pyrexia subjects affected / exposed occurrences (all)	18 / 136 (13.24%) 28  24 / 136 (17.65%) 31  9 / 136 (6.62%) 9  19 / 136 (13.97%) 22  20 / 136 (14.71%) 30	12 / 135 (8.89%) 19  27 / 135 (20.00%) 40  3 / 135 (2.22%) 3  11 / 135 (8.15%) 13  18 / 135 (13.33%) 22	
Respiratory, thoracic and mediastinal disorders Cough subjects affected / exposed occurrences (all)  Dyspnoea	21 / 136 (15.44%) 23	25 / 135 (18.52%) 32	

subjects affected / exposed occurrences (all)	12 / 136 (8.82%) 13	14 / 135 (10.37%) 18	
Haemoptysis subjects affected / exposed occurrences (all)	8 / 136 (5.88%) 8	8 / 135 (5.93%) 17	
Pleural effusion subjects affected / exposed occurrences (all)	3 / 136 (2.21%) 3	6 / 135 (4.44%) 6	
Productive cough subjects affected / exposed occurrences (all)	8 / 136 (5.88%) 9	11 / 135 (8.15%) 12	
Psychiatric disorders Anxiety subjects affected / exposed occurrences (all)	5 / 136 (3.68%) 5	2 / 135 (1.48%) 2	
Insomnia subjects affected / exposed occurrences (all)	13 / 136 (9.56%) 13	16 / 135 (11.85%) 17	
Investigations Blood creatine phosphokinase increased subjects affected / exposed occurrences (all)	6 / 136 (4.41%) 6	3 / 135 (2.22%) 4	
Alanine aminotransferase increased subjects affected / exposed occurrences (all)	43 / 136 (31.62%) 67	41 / 135 (30.37%) 69	
Aspartate aminotransferase increased subjects affected / exposed occurrences (all)	37 / 136 (27.21%) 57	40 / 135 (29.63%) 75	
Bilirubin conjugated increased subjects affected / exposed occurrences (all)	6 / 136 (4.41%) 6	4 / 135 (2.96%) 5	
Blood alkaline phosphatase increased subjects affected / exposed occurrences (all)	6 / 136 (4.41%) 9	4 / 135 (2.96%) 6	
Blood bilirubin increased			

subjects affected / exposed	14 / 136 (10.29%)	8 / 135 (5.93%)
occurrences (all)	15	17
Blood creatinine increased		
subjects affected / exposed	22 / 136 (16.18%)	10 / 135 (7.41%)
occurrences (all)	25	10
Blood lactate dehydrogenase increased		
subjects affected / exposed	8 / 136 (5.88%)	11 / 135 (8.15%)
occurrences (all)	10	19
Blood urea increased		
subjects affected / exposed	5 / 136 (3.68%)	3 / 135 (2.22%)
occurrences (all)	5	4
Fibrin D dimer increased		
subjects affected / exposed	2 / 136 (1.47%)	5 / 135 (3.70%)
occurrences (all)	2	6
Gamma-glutamyltransferase increased		
subjects affected / exposed	13 / 136 (9.56%)	5 / 135 (3.70%)
occurrences (all)	17	8
Lymphocyte count decreased		
subjects affected / exposed	12 / 136 (8.82%)	22 / 135 (16.30%)
occurrences (all)	47	52
Neutrophil count decreased		
subjects affected / exposed	50 / 136 (36.76%)	59 / 135 (43.70%)
occurrences (all)	175	188
Neutrophil count increased		
subjects affected / exposed	5 / 136 (3.68%)	4 / 135 (2.96%)
occurrences (all)	7	6
Platelet count decreased		
subjects affected / exposed	37 / 136 (27.21%)	51 / 135 (37.78%)
occurrences (all)	64	107
SARS-CoV-2 test positive		
subjects affected / exposed	16 / 136 (11.76%)	13 / 135 (9.63%)
occurrences (all)	17	15
Weight decreased		



subjects affected / exposed occurrences (all)	18 / 136 (13.24%) 18	16 / 135 (11.85%) 20	
Weight increased subjects affected / exposed occurrences (all)	14 / 136 (10.29%) 17	18 / 135 (13.33%) 23	
White blood cell count decreased subjects affected / exposed occurrences (all)	54 / 136 (39.71%) 166	61 / 135 (45.19%) 196	
Cardiac disorders Supraventricular extrasystoles subjects affected / exposed occurrences (all)	4 / 136 (2.94%) 7	5 / 135 (3.70%) 5	
Nervous system disorders Dizziness subjects affected / exposed occurrences (all)	7 / 136 (5.15%) 7	12 / 135 (8.89%) 16	
Dysgeusia subjects affected / exposed occurrences (all)	4 / 136 (2.94%) 5	7 / 135 (5.19%) 7	
Headache subjects affected / exposed occurrences (all)	12 / 136 (8.82%) 13	12 / 135 (8.89%) 16	
Hypoaesthesia subjects affected / exposed occurrences (all)	2 / 136 (1.47%) 2	7 / 135 (5.19%) 7	
Paraesthesia subjects affected / exposed occurrences (all)	5 / 136 (3.68%) 5	0 / 135 (0.00%) 0	
Peripheral sensory neuropathy subjects affected / exposed occurrences (all)	12 / 136 (8.82%) 13	8 / 135 (5.93%) 8	
Blood and lymphatic system disorders Leukopenia subjects affected / exposed occurrences (all)	13 / 136 (9.56%) 40	11 / 135 (8.15%) 42	
Anaemia			

subjects affected / exposed	81 / 136 (59.56%)	90 / 135 (66.67%)	
occurrences (all)	142	175	
Neutropenia			
subjects affected / exposed	11 / 136 (8.09%)	12 / 135 (8.89%)	
occurrences (all)	21	19	
Lymphopenia			
subjects affected / exposed	5 / 136 (3.68%)	3 / 135 (2.22%)	
occurrences (all)	20	11	
Thrombocytopenia			
subjects affected / exposed	8 / 136 (5.88%)	13 / 135 (9.63%)	
occurrences (all)	22	17	
Eye disorders			
Lacrimation increased			
subjects affected / exposed	1 / 136 (0.74%)	6 / 135 (4.44%)	
occurrences (all)	1	6	
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	13 / 136 (9.56%)	5 / 135 (3.70%)	
occurrences (all)	14	5	
Constipation			
subjects affected / exposed	40 / 136 (29.41%)	45 / 135 (33.33%)	
occurrences (all)	56	65	
Diarrhoea			
subjects affected / exposed	25 / 136 (18.38%)	21 / 135 (15.56%)	
occurrences (all)	28	27	
Gastroesophageal reflux disease			
subjects affected / exposed	5 / 136 (3.68%)	4 / 135 (2.96%)	
occurrences (all)	5	6	
Nausea			
subjects affected / exposed	51 / 136 (37.50%)	38 / 135 (28.15%)	
occurrences (all)	98	50	
Stomatitis			
subjects affected / exposed	8 / 136 (5.88%)	14 / 135 (10.37%)	
occurrences (all)	8	15	
Vomiting			

subjects affected / exposed occurrences (all)	30 / 136 (22.06%) 59	24 / 135 (17.78%) 36	
Skin and subcutaneous tissue disorders			
Alopecia			
subjects affected / exposed	26 / 136 (19.12%)	25 / 135 (18.52%)	
occurrences (all)	28	25	
Pruritus			
subjects affected / exposed	8 / 136 (5.88%)	29 / 135 (21.48%)	
occurrences (all)	10	44	
Rash			
subjects affected / exposed	27 / 136 (19.85%)	42 / 135 (31.11%)	
occurrences (all)	43	62	
Rash maculo-papular			
subjects affected / exposed	4 / 136 (2.94%)	5 / 135 (3.70%)	
occurrences (all)	4	5	
Endocrine disorders			
Hypothyroidism			
subjects affected / exposed	16 / 136 (11.76%)	21 / 135 (15.56%)	
occurrences (all)	18	23	
Hyperthyroidism			
subjects affected / exposed	8 / 136 (5.88%)	10 / 135 (7.41%)	
occurrences (all)	10	12	
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	10 / 136 (7.35%)	6 / 135 (4.44%)	
occurrences (all)	13	10	
Muscular weakness			
subjects affected / exposed	5 / 136 (3.68%)	7 / 135 (5.19%)	
occurrences (all)	5	7	
Myalgia			
subjects affected / exposed	5 / 136 (3.68%)	5 / 135 (3.70%)	
occurrences (all)	6	8	
Pain in extremity			
subjects affected / exposed	9 / 136 (6.62%)	10 / 135 (7.41%)	
occurrences (all)	10	18	
Back pain			

subjects affected / exposed occurrences (all)	8 / 136 (5.88%) 8	8 / 135 (5.93%) 8	
Infections and infestations			
COVID-19			
subjects affected / exposed	15 / 136 (11.03%)	20 / 135 (14.81%)	
occurrences (all)	24	24	
Pneumonia			
subjects affected / exposed	14 / 136 (10.29%)	12 / 135 (8.89%)	
occurrences (all)	14	18	
Upper respiratory tract infection			
subjects affected / exposed	9 / 136 (6.62%)	9 / 135 (6.67%)	
occurrences (all)	11	11	
Urinary tract infection			
subjects affected / exposed	5 / 136 (3.68%)	4 / 135 (2.96%)	
occurrences (all)	6	4	
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	42 / 136 (30.88%)	37 / 135 (27.41%)	
occurrences (all)	55	42	
Dehydration			
subjects affected / exposed	6 / 136 (4.41%)	4 / 135 (2.96%)	
occurrences (all)	40	25	
Hypercholesterolaemia			
subjects affected / exposed	1 / 136 (0.74%)	5 / 135 (3.70%)	
occurrences (all)	3	8	
Hyperglycaemia			
subjects affected / exposed	16 / 136 (11.76%)	13 / 135 (9.63%)	
occurrences (all)	19	28	
Hypertriglyceridaemia			
subjects affected / exposed	5 / 136 (3.68%)	7 / 135 (5.19%)	
occurrences (all)	8	21	
Hyperuricaemia			
subjects affected / exposed	8 / 136 (5.88%)	3 / 135 (2.22%)	
occurrences (all)	18	4	
Hypoalbuminaemia			

subjects affected / exposed	23 / 136 (16.91%)	30 / 135 (22.22%)	
occurrences (all)	34	53	
Hypocalcaemia			
subjects affected / exposed	6 / 136 (4.41%)	7 / 135 (5.19%)	
occurrences (all)	9	10	
Hypokalaemia			
subjects affected / exposed	17 / 136 (12.50%)	23 / 135 (17.04%)	
occurrences (all)	24	36	
Hypomagnesaemia			
subjects affected / exposed	6 / 136 (4.41%)	6 / 135 (4.44%)	
occurrences (all)	8	11	
Hyponatraemia			
subjects affected / exposed	21 / 136 (15.44%)	20 / 135 (14.81%)	
occurrences (all)	26	36	
Hypophosphataemia			
subjects affected / exposed	4 / 136 (2.94%)	5 / 135 (3.70%)	
occurrences (all)	4	5	

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
06 April 2021	Original Protocol
11 June 2021	Amendment 1.0
30 March 2022	Amendment 2.0
23 September 2022	Amendment 3.0

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

NA
----

Notes: